{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T06:31:10Z","timestamp":1770273070918,"version":"3.49.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Osteoporosis is a common metabolic bone disease in the elderly, and its incidence continues to rise with the global aging population. Calcitonin analogs (including synthetic salmon, human, and porcine calcitonin preparations) are a classic treatment option for osteoporosis; however, the safety and efficacy of their long-term use remain controversial despite widespread application.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aims to systematically assess the safety and efficacy of long-term use of calcitonin analogs in the treatment of osteoporosis in the elderly through pharmacovigilance analysis and meta-analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The study evaluated the long-term effectiveness and adverse effects of calcitonin analogs using pharmacovigilance data from the FAERS database and a meta-analysis of randomized controlled trials (RCTs). The pharmacovigilance analysis included adverse event data from osteoporosis patients aged 65 and older from 2004 to 2023, and signal detection was performed using the reporting odds ratio (ROR), proportional reporting ratio (PRR), and Bayesian confidence propagation neural network (BCPNN) methods. The meta-analysis included RCT studies related to calcitonin published after 2010, and a random-effects model was used to calculate the hazard ratio (HR) with a 95% confidence interval.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Pharmacovigilance analysis revealed that nasal discomfort (ROR = 283.4, PRR = 264.5, IC = 7.3, IC<jats:sub>025<\/jats:sub> = 6.8) and abnormal product odor (ROR = 206.2, PRR = 201.9, IC = 7.1, IC<jats:sub>025<\/jats:sub> = 6.1) were the most significant adverse reactions associated with calcitonin. Meta-analysis results showed no significant effect of calcitonin analogs in preventing new non-vertebral fractures and vertebral fractures (HR = 0.97, 95% CI: 0.76\u20131.24; HR = 0.93, 95% CI: 0.77\u20131.14). Changes in lumbar spine and femoral neck bone mineral density showed a slight upward trend but were not statistically significant. The analysis of NTx-1 levels (N-terminal telopeptide of type I collagen, a marker of bone resorption) revealed substantial heterogeneity, with significant variation in results across studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Long-term use of calcitonin analogs for the treatment of osteoporosis in the elderly does not confer additional benefits and instead increases the risk of adverse reactions.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1514387","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:25:15Z","timestamp":1759123515000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["The safety and efficacy of long-term use of calcitonin analogs in the treatment of osteoporosis in the elderly: a pharmacovigilance and RCT meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Lingjie","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sui","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.ecl.2012.04.006","article-title":"Pathophysiology of osteoporosis: new mechanistic insights","volume":"41","author":"Armas","year":"2012","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"B2","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1080\/17425255.2016.1175436","article-title":"Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis","volume":"12","author":"Bandeira","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1002\/jbmr.1602","article-title":"A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the oral calcitonin in postmenopausal osteoporosis (ORACAL) trial","volume":"27","author":"Binkley","year":"2012","journal-title":"J. Bone Min. Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00198-019-04997-6","article-title":"Efficacy and safety of elcatonin in postmenopausal women with osteoporosis: a systematic review with network meta-analysis of randomized clinical trials","volume":"30","author":"Chen","year":"2019","journal-title":"Osteoporos. Int."},{"key":"B5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/s0303-7207(01)00530-5","article-title":"Calcitonin is a prostate epithelium-derived growth stimulatory peptide","volume":"181","author":"Chien","year":"2001","journal-title":"Mol. Cell Endocrinol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/bmb\/ldaa005","article-title":"The epidemiology of osteoporosis","volume":"133","author":"Clynes","year":"2020","journal-title":"Br. Med. Bull."},{"key":"B7","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/j.1742-1241.1994.tb09806.x","article-title":"Calcitonins and osteoporosis","volume":"48","author":"Gennari","year":"1994","journal-title":"Br. J. Clin. Pract."},{"key":"B8","doi-asserted-by":"publisher","first-page":"6682","DOI":"10.1039\/d3cc01140b","article-title":"Enhancing the gastrointestinal stability of salmon calcitonin through peptide stapling","volume":"59","author":"Ghareeb","year":"2023","journal-title":"Chem. Commun. (Camb)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.bone.2016.07.019","article-title":"A randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D","volume":"91","author":"Henriksen","year":"2016","journal-title":"Bone"},{"key":"B10","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","article-title":"Osteoporosis in the european union: medical management, epidemiology and economic burden. A report prepared in collaboration with the international osteoporosis foundation (IOF) and the european Federation of pharmaceutical industry associations (EFPIA)","volume":"8","author":"Hernlund","year":"2013","journal-title":"Arch. Osteoporos."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1007\/s00198-010-1495-8","article-title":"Alendronate is more effective than elcatonin in improving pain and quality of life in postmenopausal women with osteoporosis","volume":"22","author":"Iwamoto","year":"2011","journal-title":"Osteoporos. Int."},{"key":"B12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.9734\/jpri\/2024\/v36i117603","article-title":"Emerging protein and peptide therapeutics for osteoporosis: advances in anabolic and catabolic treatments","volume":"36","author":"Kuril","year":"2024","journal-title":"J. Pharm. Res. Int."},{"key":"B13","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3760\/cma.j.issn.0366-6999.20121626","article-title":"Comparison of parathyroid hormone (1-34) and elcatonin in postmenopausal women with osteoporosis: an 18-month randomized, multicenter controlled trial in China","volume":"126","author":"Li","year":"2013","journal-title":"Chin. Med. J. Engl."},{"key":"B14","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1021\/acsami.2c19241","article-title":"Composite separable microneedles for transdermal delivery and controlled release of salmon calcitonin for osteoporosis therapy","volume":"15","author":"Li","year":"2023","journal-title":"ACS Appl. Mater Interfaces"},{"key":"B15","article-title":"StatPearls treasure island (FL) ineligible companies. Disclosure: ayoola awosika declares no relevant financial relationships with ineligible companies","volume-title":"Disclosure: Ishwarlal jialal declares no relevant financial relationships with ineligible companies","author":"McLaughlin","year":"2024"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.2174\/1381612033453622","article-title":"Calcitonin for osteoporosis and bone pain","volume":"9","author":"Mehta","year":"2003","journal-title":"Curr. Pharm. Des."},{"key":"B17","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1097\/GRF.0000000000000572","article-title":"Bone health and osteoporosis prevention and treatment","volume":"63","author":"Munoz","year":"2020","journal-title":"Clin. Obstet. Gynecol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e1494","DOI":"10.1210\/clinem\/dgaa933","article-title":"Letter to the editor from murad: efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis","volume":"106","author":"Murad","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.afos.2020.02.001","article-title":"Association between elcatonin use and cancer risk in Japan: a follow-up study after a randomized, double-blind, placebo-controlled study of once-weekly elcatonin in primary postmenopausal osteoporosis","volume":"6","author":"Okamoto","year":"2020","journal-title":"Osteoporos. Sarcopenia"},{"key":"B20","first-page":"865","article-title":"China guideline for diagnosis and treatment of senile osteoporosis","volume":"16","author":"Tianzun","year":"2023","journal-title":"Chin. J. Bone Jt. Surg."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.62347\/ZMAL4724","article-title":"The effects of alfacalcidol combined with calcitonin in the treatment of osteoporosis and its influence on levels of inflammation","volume":"16","author":"Rui","year":"2024","journal-title":"Am. J. Transl. Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1186\/s13018-021-02772-0","article-title":"The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis","volume":"16","author":"Salari","year":"2021","journal-title":"J. Orthop. Surg. Res."},{"key":"B23","first-page":"600","article-title":"Calcitonin: a useful old friend","volume":"20","author":"Srinivasan","year":"2020","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"B24","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1080\/03007995.2018.1498780","article-title":"A randomized, double-blind, placebo-controlled study of once weekly elcatonin in primary postmenopausal osteoporosis","volume":"35","author":"Sugimoto","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"key":"B25","doi-asserted-by":"publisher","first-page":"4259","DOI":"10.1210\/jc.2014-2239","article-title":"Calcitonin nasal spray and increased cancer risk: a population-based nested case-control study","volume":"99","author":"Sun","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B26","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s00774-016-0791-6","article-title":"Effectiveness of elcatonin for alleviating pain and inhibiting bone resorption in patients with osteoporotic vertebral fractures","volume":"35","author":"Tanaka","year":"2017","journal-title":"J. Bone Mineral Metabolism"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.3390\/cells12131675","article-title":"Calcitonin related polypeptide alpha mediates oral cancer pain","volume":"12","author":"Tu","year":"2023","journal-title":"Cells"},{"key":"B28","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s11657-020-00798-1","article-title":"Anti-osteoporosis medication treatment pattern after osteoporotic fracture during 2010-2016 in Fujian, China","volume":"15","author":"Wang","year":"2020","journal-title":"Arch. Osteoporos."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e11880","DOI":"10.1016\/j.heliyon.2022.e11880","article-title":"Efficacy and safety of pharmacologic therapies for prevention of osteoporotic vertebral fractures in postmenopausal women","volume":"9","author":"Wei","year":"2023","journal-title":"Heliyon"},{"key":"B30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00198-015-3339-z","article-title":"Does salmon calcitonin cause cancer? A review and meta-analysis","volume":"27","author":"Wells","year":"2016","journal-title":"Osteoporos. Int."},{"key":"B31","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jconrel.2021.08.056","article-title":"Spatiotemporally controlled calcitonin delivery: long-term and targeted therapy of skeletal diseases","volume":"338","author":"Yu","year":"2021","journal-title":"J. Control Release"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1514387\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:25:16Z","timestamp":1759123516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1514387\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":31,"alternative-id":["10.3389\/fphar.2025.1514387"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1514387","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"article-number":"1514387"}}